RaQualia Pharma (TSE:4579) Total Tax Payable: 円11 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4579 RaQualia Pharma Inc TSE:4579
54 GF Score
Price 円517.00
GF Value 円905.15
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is RaQualia Pharma Total Tax Payable?

RaQualia Pharma TSE:4579 +0.39% 54 Total Tax Payable is 円11 Mil as of Mar. 2026. GuruFocus rates TSE:4579 with a GF Score™ of 54/100 and a GF Value™ of 円905.15 (Significantly Undervalued). The stock has 3 warning signs investors should review.

RaQualia Pharma's Total Tax Payable for the quarter that ended in Mar. 2026 was 円11 Mil.

RaQualia Pharma's quarterly Total Tax Payable increased from Sep. 2025 (円37 Mil) to Dec. 2025 (円55 Mil) but then declined from Dec. 2025 (円55 Mil) to Mar. 2026 (円11 Mil).

RaQualia Pharma's annual Total Tax Payable increased from Dec. 2023 (円20 Mil) to Dec. 2024 (円28 Mil) and increased from Dec. 2024 (円28 Mil) to Dec. 2025 (円55 Mil).

RaQualia Pharma Total Tax Payable Related Terms

RaQualia Pharma Total Tax Payable Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Total Tax Payable Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Tax Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 117.88 30.96 19.69 28.04 54.78

RaQualia Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.40 18.92 36.92 54.78 11.03
TSE:4579
54GF Score
RaQualia Pharma Inc TSE:4579
Total Tax Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaQualia Pharma Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Frequently Asked Questions Learn more about Total Tax Payable →
What does a Total Tax Payable of 円11 Mil mean?
RaQualia Pharma (TSE:4579) has a Total Tax Payable of 円11 Mil as of Mar. 2026. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on RaQualia Pharma and its competitors.
Is RaQualia Pharma's Total Tax Payable too high?
RaQualia Pharma's current Total Tax Payable is 円11 Mil. Overall, RaQualia Pharma has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Total Tax Payable compare to VRTX and REGN?
RaQualia Pharma's Total Tax Payable of 円11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Tax Payable for a Biotechnology company?
A good Total Tax Payable depends on the Biotechnology industry context. However, Total Tax Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Tax Payable mean?
A high Total Tax Payable can signal that a stock is expensive relative to its fundamentals. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current Total Tax Payable is 円11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円905.15, compared to a current price of 円517.00 — trading 42.9% below its estimated fair value. The current Total Tax Payable is 円11 Mil. RaQualia Pharma's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Tax Payable calculated?
Total Tax Payable is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Total Tax Payable is 円11 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued. The current stock price of 円517.00 is trading 42.9% below its estimated GF Value™ of 円905.15. GuruFocus considers RaQualia Pharma to be Significantly Undervalued.

Key valuation signals for TSE:4579:

  • Total Tax Payable: 円11 Mil
  • GF Value™: 円905.15 vs. price of 円517.00 (42.9% below fair value)
  • GF Score™: 54/100 with 3 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
54GF Score

Get the complete analysis for TSE:4579

Total Tax Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円517.00
Price
円905.15
GF Value